EPRSQ

 
Common Stock SEC Reporting - Delinquent
Pink No Information
Contact Info
  • 699 Boylston Street
  • Eighth Floor
  • Boston, MA 02116

  • Phone: (617) 600-3497
Business Description

Not Available


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Not Available
Latest Report Mar 31, 2016 10-Q
CIK 0001135906
Fiscal Year End 12/31
OTC Marketplace Pink No Information
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Robert Forrester CFO, EVP
Jason F. Cole Senior VP, General Counsel
Company Directors
Not Available
Service Providers
Accounting/Auditing Firm

Not Available
Securities Counsel

Not Available
Investor Relations Firm

Not Available
Company History
  • Note = On July 25, 2016, the Company filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. SS 101 et seq. in the United States Bankruptcy Court for the District of Massachusetts
  • Formerly=Zalicus Inc. until 7-2014
  • Formerly=CombinatoRx, Inc. until 9-2010
EPRSQ Security Details
Share Structure
Market Value1 $445,134 a/o Sep 19, 2017
Authorized Shares Not Available
Outstanding Shares 26,184,349 a/o Mar 25, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.001
Transfer Agent(s)
Computershare
Shareholders
Shareholders of Record 53 a/o Mar 29, 2016
Short Selling Data
Short Interest 9,317 (1.3%)
Aug 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security